Noemi Karsai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Noemi Karsai has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Stephen J. Hill
Cell Signalling and Pharmacology Research Group, Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, UK
2 shared publications Ana Montero-Calle
Chronic Disease Programme (UFIEC), Instituto de Salud Carlos III, Madrid, Spain
1 shared publication- Anna Janovicz
Institute of Translational Medicine, Semmelweis University, 1085 Budapest, Hungary
1 shared publication Antonio J. Sánchez-López
Neuroimmunology Unit, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain
1 shared publication- Balázs Besztercei
Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary
1 shared publication Belén Almoguera Pérez-Cejuela
Department of Gynecology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 29 July 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (8) , 1107
Characterising C-X-C Chemokine Receptor 4 Dynamics in the Cell Membrane Using Fluorescence Fluctuation Spectroscopy
The spatial organisation of plasma membrane proteins such as G protein-coupled receptors (GPCRs) plays a critical role in regulating cell signalling, function, and ultimately cell fate. Resolving this organisation requires techniques capable of probing dynamics at the single-molecule level with high spatial and temporal resolution. In this study, we employ the complementary fluorescence fluctuation spectroscopy approaches, Fluorescence Correlation Spectroscopy (FCS), Photon Counting Histogram Analysis (PCH), Raster Image Correlation Spectroscopy (RICS) and Number and Brightness Analysis (N&B), in conjunction with Fluorescence Recovery After Photobleaching (FRAP), to investigate the membrane organisation of the C-X-C chemokine receptor 4 (CXCR4), a GPCR known to undergo ligand-induced reorganisation. At the nanoscale, FCS highlighted opposing effects on diffusion after agonist (CXCL12) and inverse agonist (IT1t) treatment, whilst RICS also showed ligand-mediated changes in particle number. Both single-point and image-based brightness analyses (PCH and N&B) showed increased brightness after CXCL12 treatment, consistent with the pre-internalisation clustering of CXCR4. At the microscale, FRAP showed an increase in immobile CXCR4, not visible to FFS approaches, following CXCL12 stimulation. This integrated approach, performed on a single commercial confocal microscope, provides valuable insight into the reorganisation of CXCR4 in the plasma membrane over a range of temporal and spatial scales, which are not detectable using standard imaging.
- 29 July 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (8) , 1107
Open AccessCharacterising C-X-C Chemokine Receptor 4 Dynamics in the Cell Membrane Using Fluorescence Fluctuation Spectroscopy
The spatial organisation of plasma membrane proteins such as G protein-coupled receptors (GPCRs) plays a critical role in regulating cell signalling, function, and ultimately cell fate. Resolving this organisation requires techniques capable of probing dynamics at the single-molecule level with high spatial and temporal resolution. In this study, we employ the complementary fluorescence fluctuation spectroscopy approaches, Fluorescence Correlation Spectroscopy (FCS), Photon Counting Histogram Analysis (PCH), Raster Image Correlation Spectroscopy (RICS) and Number and Brightness Analysis (N&B), in conjunction with Fluorescence Recovery After Photobleaching (FRAP), to investigate the membrane organisation of the C-X-C chemokine receptor 4 (CXCR4), a GPCR known to undergo ligand-induced reorganisation. At the nanoscale, FCS highlighted opposing effects on diffusion after agonist (CXCL12) and inverse agonist (IT1t) treatment, whilst RICS also showed ligand-mediated changes in particle number. Both single-point and image-based brightness analyses (PCH and N&B) showed increased brightness after CXCL12 treatment, consistent with the pre-internalisation clustering of CXCR4. At the microscale, FRAP showed an increase in immobile CXCR4, not visible to FFS approaches, following CXCL12 stimulation. This integrated approach, performed on a single commercial confocal microscope, provides valuable insight into the reorganisation of CXCR4 in the plasma membrane over a range of temporal and spatial scales, which are not detectable using standard imaging.
- Open Access
- 11 May 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (25) , 2436-2451
Cannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response
Acquired or innate lack of response to standard HER2-targeted therapies remains a clinical issue in patients with HER2-positive breast cancer. Here, we investigated the role of the cannabinoid CB 2 receptor (CB 2 R) in trastuzumab resistance. In human breast cancer samples, a decreased expression of HER2-CB 2 R heterodimers following neoadjuvant treatment, due to CB 2 R downregulation, was linked to poor long-term outcomes. Using various preclinical models, we demonstrate that CB 2 R drives trastuzumab resistance. Mechanistically, CB 2 R loss enabled cancer cells to evade antitumor IFN-γ signaling while promoting a shift from HER2-CB 2 R to HER2-EGFR heterodimers, thus reducing dependence on HER2 and increasing reliance on EGFR-mediated pathways. Moreover, EGFR inhibition restored trastuzumab sensitivity. In summary, we reveal an unprecedented role for CB 2 R as a key regulator of oncogenic and immune signaling in response to anti-HER2 therapy and its potential as a predictive biomarker of therapeutic efficacy. We also propose dual HER2/EGFR targeting and non-CB 2 R-selective cannabinoid therapies as potential strategies to overcome CB 2 R-mediated trastuzumab resistance. Together, these findings position the endocannabinoid system as a pivotal and actionable node to elucidate, anticipate, and counteract resistance to HER2-targeted therapies.
- 11 May 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (25) , 2436-2451
Open AccessCannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response
Acquired or innate lack of response to standard HER2-targeted therapies remains a clinical issue in patients with HER2-positive breast cancer. Here, we investigated the role of the cannabinoid CB 2 receptor (CB 2 R) in trastuzumab resistance. In human breast cancer samples, a decreased expression of HER2-CB 2 R heterodimers following neoadjuvant treatment, due to CB 2 R downregulation, was linked to poor long-term outcomes. Using various preclinical models, we demonstrate that CB 2 R drives trastuzumab resistance. Mechanistically, CB 2 R loss enabled cancer cells to evade antitumor IFN-γ signaling while promoting a shift from HER2-CB 2 R to HER2-EGFR heterodimers, thus reducing dependence on HER2 and increasing reliance on EGFR-mediated pathways. Moreover, EGFR inhibition restored trastuzumab sensitivity. In summary, we reveal an unprecedented role for CB 2 R as a key regulator of oncogenic and immune signaling in response to anti-HER2 therapy and its potential as a predictive biomarker of therapeutic efficacy. We also propose dual HER2/EGFR targeting and non-CB 2 R-selective cannabinoid therapies as potential strategies to overcome CB 2 R-mediated trastuzumab resistance. Together, these findings position the endocannabinoid system as a pivotal and actionable node to elucidate, anticipate, and counteract resistance to HER2-targeted therapies.
- Open Access
- 22 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 6872
LPA-Induced Thromboxane A2-Mediated Vasoconstriction Is Limited to Poly-Unsaturated Molecular Species in Mouse Aortas
We have previously reported that, in aortic rings, 18:1 lysophosphatidic acid (LPA) can induce both vasodilation and vasoconstriction depending on the integrity of the endothelium. The predominant molecular species generated in blood serum are poly-unsaturated LPA species, yet the vascular effects of these species are largely unexplored. We aimed to compare the vasoactive effects of seven naturally occurring LPA species in order to elucidate their potential pathophysiological role in vasculopathies. Vascular tone was measured using myography, and thromboxane A2 (TXA2) release was detected by ELISA in C57Bl/6 mouse aortas. The Ca2+-responses to LPA-stimulated primary isolated endothelial cells were measured by Fluo-4 AM imaging. Our results indicate that saturated molecular species of LPA elicit no significant effect on the vascular tone of the aorta. In contrast, all 18 unsaturated carbon-containing (C18) LPAs (18:1, 18:2, 18:3) were effective, with 18:1 LPA being the most potent. However, following inhibition of cyclooxygenase (COX), these LPAs induced similar vasorelaxation, primarily indicating that the vasoconstrictor potency differed among these species. Indeed, C18 LPA evoked a similar Ca2+-signal in endothelial cells, whereas in endothelium-denuded aortas, the constrictor activity increased with the level of unsaturation, correlating with TXA2 release in intact aortas. COX inhibition abolished TXA2 release, and the C18 LPA induced vasoconstriction. In conclusion, polyunsaturated LPA have markedly increased TXA2-releasing and vasoconstrictor capacity, implying potential pathophysiological consequences in vasculopathies.
- 22 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 6872
Open AccessLPA-Induced Thromboxane A2-Mediated Vasoconstriction Is Limited to Poly-Unsaturated Molecular Species in Mouse Aortas
We have previously reported that, in aortic rings, 18:1 lysophosphatidic acid (LPA) can induce both vasodilation and vasoconstriction depending on the integrity of the endothelium. The predominant molecular species generated in blood serum are poly-unsaturated LPA species, yet the vascular effects of these species are largely unexplored. We aimed to compare the vasoactive effects of seven naturally occurring LPA species in order to elucidate their potential pathophysiological role in vasculopathies. Vascular tone was measured using myography, and thromboxane A2 (TXA2) release was detected by ELISA in C57Bl/6 mouse aortas. The Ca2+-responses to LPA-stimulated primary isolated endothelial cells were measured by Fluo-4 AM imaging. Our results indicate that saturated molecular species of LPA elicit no significant effect on the vascular tone of the aorta. In contrast, all 18 unsaturated carbon-containing (C18) LPAs (18:1, 18:2, 18:3) were effective, with 18:1 LPA being the most potent. However, following inhibition of cyclooxygenase (COX), these LPAs induced similar vasorelaxation, primarily indicating that the vasoconstrictor potency differed among these species. Indeed, C18 LPA evoked a similar Ca2+-signal in endothelial cells, whereas in endothelium-denuded aortas, the constrictor activity increased with the level of unsaturation, correlating with TXA2 release in intact aortas. COX inhibition abolished TXA2 release, and the C18 LPA induced vasoconstriction. In conclusion, polyunsaturated LPA have markedly increased TXA2-releasing and vasoconstrictor capacity, implying potential pathophysiological consequences in vasculopathies.
- Open Access
- 20 November 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Differential interaction patterns of opioid analgesics with µ opioid receptors correlate with ligand-specific voltage sensitivity
The µ opioid receptor (MOR) is the key target for analgesia, but the application of opioids is accompanied by several issues. There is a wide range of opioid analgesics, differing in their chemical structure and their properties of receptor activation and subsequent effects. A better understanding of ligand-receptor interactions and the resulting effects is important. Here, we calculated the respective binding poses for several opioids and analyzed interaction fingerprints between ligand and receptor. We further corroborated the interactions experimentally by cellular assays. As MOR was observed to display ligand-induced modulation of activity due to changes in membrane potential, we further analyzed the effects of voltage sensitivity on this receptor. Combining in silico and in vitro approaches, we defined discriminating interaction patterns responsible for ligand-specific voltage sensitivity and present new insights into their specific effects on activation of the MOR.
- 20 November 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessDifferential interaction patterns of opioid analgesics with µ opioid receptors correlate with ligand-specific voltage sensitivity
The µ opioid receptor (MOR) is the key target for analgesia, but the application of opioids is accompanied by several issues. There is a wide range of opioid analgesics, differing in their chemical structure and their properties of receptor activation and subsequent effects. A better understanding of ligand-receptor interactions and the resulting effects is important. Here, we calculated the respective binding poses for several opioids and analyzed interaction fingerprints between ligand and receptor. We further corroborated the interactions experimentally by cellular assays. As MOR was observed to display ligand-induced modulation of activity due to changes in membrane potential, we further analyzed the effects of voltage sensitivity on this receptor. Combining in silico and in vitro approaches, we defined discriminating interaction patterns responsible for ligand-specific voltage sensitivity and present new insights into their specific effects on activation of the MOR.